

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

DC2.4

RRID:CVCL_J409

Type: Cell Line

Proper Citation

Hysigen Cat# TCM-C832, RRID:CVCL_J409

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_J409

Proper Citation: Hysigen Cat# TCM-C832, RRID:CVCL_J409

Description: Cell line DC2.4 is a Transformed cell line with a species of origin Mus musculus (Mouse)

Sex: Sex unspecified

Defining Citation: [PMID:9058806](#)

Category: Transformed cell line

Organism: Mus musculus (Mouse)

Name: DC2.4

Synonyms: DC 2.4

Cross References: EFO:EFO_0022830, CLS:305515, Hysigen:TCM-C832, Millipore:SCC142, Wikidata:Q54828620

ID: CVCL_J409

Vendor: Hysigen

Catalog Number: TCM-C832

Record Creation Time: 20260408T072943+0000

Record Last Update: 20260905T185249+0000

Ratings and Alerts

No rating or validation information has been found for DC2.4.

No alerts have been found for DC2.4.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 271 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Yu M, et al. (2026) Development of a Synergistic Photothermal-Immunotherapy Nanoplatfrom via Codelivery of a STING Agonist and Cyanine Dye against Triple-Negative Breast Cancer. ACS applied materials & interfaces, 18(7), 11162.

Zhao Y, et al. (2026) Dual Covalent Targeting of STING Cysteines 292/309 Disrupts Functional Oligomerization and Enables Potent Antagonist Development. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(32), e22764.

Zuo B, et al. (2026) Combination of exosome vaccines, lenvatinib, and anti-PD-1 eradicates tumor in autochthonous hepatocellular carcinoma mice. Cell reports. Medicine, 102933.

Zhang B, et al. (2026) Immunometabolic Rewiring of Dendritic Cells to Overcome Glutamine-Driven Immune Suppression in Colorectal Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(5), e13986.

He G, et al. (2026) Bimetallic Peroxide Nanocomposites-Driven Redox Dyshomeostasis to Activate Sequential Cuproptosis and Pyroptosis for Amplified Tumor Immunotherapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(18), e12470.

Tong S, et al. (2026) Tripartite motif 13 orchestrates endoplasmic reticulum-associated degradation and endoplasmic reticulum-phagy to modulate dendritic cell-mediated immune responses in sepsis. Burns & trauma, 14, tkaf077.

Yan H, et al. (2026) Autophagy-enhanced hybrid pyroptotic vesicles as personalized vaccines for cancer immunotherapy. Journal of nanobiotechnology, 24(1).

Kou X, et al. (2026) Tumor-activated dual metabolic nanomodulator turns over tolerogenic tumor control and unleashes systemic immune responses. Journal of nanobiotechnology, 24(1).

Schneider P, et al. (2026) Biodegradable Carbonate Nanogels Loaded with Anti MFAP-5 siRNA for Anti-stromal Therapy of Hepatocellular Carcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(21), e10006.

Xu X, et al. (2026) Redefining Dendritic Cell Vaccines: Synergistically Co-priming DC and B Cells With Nanoparticles Loading Whole Cell Antigens Maximizes the Efficacy of DC Vaccines. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(22), e10615.

Mizuno N, et al. (2026) Characterization of a transmembrane-activating STING agonist using genetically humanized mice. *Cell reports*, 45(6), 117475.

Xu S, et al. (2025) Dual STING activation and CD47/SIRP?? blockade via chitooligosaccharide-based nanoparticles to amplify antitumor immunity. *Journal of controlled release : official journal of the Controlled Release Society*, 387, 114235.

Wu X, et al. (2025) Development of a neutralization assay and bioluminescent imaging mouse model for Dehong virus (DEHV) using a pseudovirus system. *Microbiology spectrum*, 13(5), e0155724.

Ma T, et al. (2025) Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells. *Cancer research*, 85(19), 3596.

Sun G, et al. (2025) Soft-Drug-Inspired MnSTF Nano-Adjuvant for Safe and Synergistic cGAS-STING Activation in Tumor Immunotherapy. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e15432.

Zhang M, et al. (2025) Multi-Architecture Nanovaccines Against Pseudorabies Virus and Particle Size-Governed Immune Activation Mechanisms. *Advanced healthcare materials*, e03382.

Wu J, et al. (2025) Novel Swelling-Lytic Cell Death Triggered by Cargo-Free Ionizable Lipid Nanoparticles. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e09208.

Yu Y, et al. (2024) Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy. *Molecular oncology*, 18(8), 1904.

Shang L, et al. (2024) Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers. *Cell reports. Medicine*, 5(7), 101648.

Cao M, et al. (2024) In situ label-free X-ray imaging for visualizing the localization of nanomedicines and subcellular architecture in intact single cells. *Nature protocols*, 19(1), 30.